AUA 2025: Performance of Minimal Residual Disease Detection with Urine-Derived DNA in High-Grade Bladder Cancer Patients Undergoing Recommended Repeat Transurethral Resection
AUA 2025 performance of minimal residual disease detection with urine-derived DNA, high-grade bladder cancer, recommended repeat TURBT, UroAmp.